Sujets dexamens de Pharmacie
4 janv. 2016 S(-)-enanliomers of lansoprazole inhibit (H + fK + )-. A TPase activity in isolated canine microsomes and acid formation stimulated by ...
Meeting of the Advisory Committee on Immunization and Vaccines
21 sept. 2020 models; summary of stakeholder consultation on ... Règlement sanitaire international: évaluation externe conjointe.
![Meeting of the Advisory Committee on Immunization and Vaccines Meeting of the Advisory Committee on Immunization and Vaccines](https://pdfprof.com/Listes/21/7556-21IVIR-AC_Pink_Book_sept_2020.pdf.pdf.jpg)
IVIR-AC - September 2020
MICROSOFT TEAMS - VIRTUAL MEETING WHOHEADQUARTERS, GENEVA, SWITZERLAND 21 to 25 September 2020 2 This booklet contains key background documents for the meeting of the Advisory Committee on Immunization and Vaccines-related Implementation Research (IVIR-AC) 21to 25 September 2020
This published after the IVIR-AC meeting at the
following linkǣ c/en/index4.htmlIVIR-AC - September 2020
Table of Contents Ȃ September 2020 - IVIR-AC meetingDocuments Page
1.Administrative Documents
List of IVIR-AC Members 4
IVIR-AC Terms of References 6
DOI for WHO experts and Confidentiality undertakings 72.Agenda and List of Participants
List of Participants 13
Agenda ʹͲ
3.WER summary of last IVIRAC ͵ͷ
4.Presentations
Session 1: COVID-19: Risk of SARS-CoV-2 transmission with different immunization services ͷʹSession 2: COVID-19: Frameworks and methods to guide COVID 19 vaccine development ͳͳ Session 3: WUENIC 2.0 ͳͷͺ
Session 5: RTS,S Malaria Vaccine vv{
Session 9: Burden of enteric diseases ʹIVIR-AC - September 2020
Current IVIR-AC Ȃ Advisory Committee Members
Habib Hasan Farooqui, Additional Professor, Public Health Foundation of India,Delhi, India
Mark Jit, Professor Vaccine Epidemiology, Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, Keppel Street, London, United Kingdom of Great Britain & Northern Ireland Julie Leask, Proferssor, Susan Wakil School of Nursing and Midwifery, Sydney Nursing School, Faculty of Medicine and Health, Camperdown NSW 2050, Sydney,Australia
Jean-Daniel Lelièvre, Department of Clinical Immunology INSERM, CHU Henri Mondor 51 avenue Maréchal de Lattre de Tassigny, 94010 Créteil Cedex, France Paula M. Luz, Professor, Evandro Chagas Clinical Research Institute (IPEC/ FIOCRUZ), Av. Brasil 4365, Manguinhos, 21040-360 Rio de Janeiro, BrazilDafrossa C. Lyimo
United Republic of Tanzania
Victoria Nankabirwa,
Uganda
Wilfred Ndifon,
Rwanda
Virginia Pitzer
United States of America
Stéphane Verguet
United States of America
Xuan-yi Wang, China
Joseph Wu
Hong Kong SAR, China
6DECLARATION OF INTERESTS FOR WHO EXPERTS
may have interests related to their expertise. potential conflict of interest disclosed publishedDate and title of meeting or work, including description of subject matter to be considered (if a number of
substances or processes are to be evaluated, a list should be attached by the organizer of the activity)
EMPLOYMENT AND CONSULTING
RESEARCH SUPPORT
INVESTMENT INTERESTS
INTELLECTUAL PROPERTY
PUBLIC STATEMENTS AND POSITIONS
ADDITIONAL INFORMATION
TOBACCO OR TOBACCO PRODUCTS
EXPLANATION OF "YES" RESPONSES: "yes", check
above and briefly describe the circumstances on this page. If you do not describe the nature of an interest or
if you do not provide the amount or value involved where relevant, the conflict will be assumed to be significant.
Nos. 1 - 4:
Type of interest, question
number and category (e.g.,Intellectual Property 4.a
copyrights) and basic descriptive details.Name of
company, organization, or institutionBelongs to you, a
family member, employer, research unit or other?Amount of income
or value of interest (if not disclosed, is assumed to be significant)Current
interest (or year ceased)Nos. 5-6: Describe the subject, specific circumstances, parties involved, time frame and other relevant details
DECLARATION. I hereby declare on my honour that the disclosed information is true and complete to the best of my knowledge. Should there be any change to the above information, I will promptly notify the responsible staff ofWHO and complete a new declaration of interests form that describes the changes. This includes any change
that occurs before or during the meeting or work itself and through the period up to the publication of the
final results or completion of the activity concerned.Annex C
CONFIDENTIALITY UNDERTAKING
Annex C
Initiative for Vaccine Research
Immunization Vaccines & Biologicals
Microsoft Teams - Virtual Meeting
Advisory Committee Members
Initiative for Vaccine Research
Immunization Vaccines & Biologicals
Shanghai Medical College, Fudan University,
Observers
Initiative for Vaccine Research
Immunization Vaccines & Biologicals
AInitiative for Vaccine Research
Immunization Vaccines & Biologicals
Sus an Nazarro, Kat hleen Neuzil Folak e Olayinka Soni a Pagliusi, Jame s A Platts-Mills,QIHFWLRXV'LVHDVHV&OLQLF)LIWK)ORRU2XWSDWLHQW &OLQLF-HIIHUVRQ3DUN$YH&KDUORWWHVYLOOH9$ And rew J. Pollard, Kirs ten VanniceRegional
Offices
Cuauht
émoc Ruiz Matus
:RUOInitiative for Vaccine Research
Immunization Vaccines & Biologicals
Initiative for Vaccine Research
Immunization Vaccines & Biologicals
Initiative for Vaccine Research
Immunization Vaccines & Biologicals
W Mse mburi,Olivia B
ullock, Kat herine O"Brien 20 Duration Title Content and key questions to IVIRAC Purpose Proposed speaker1200 - 1205
5" Opening of Meeting Update on global strategies and issues of
relevance to WHOFor information
K O Brien, Director, Department
of Immunization, Vaccines andBiologicals
1205-1215
10" Introduction/
Objectives of the meeting
Administrative issues
Objectives of IVIRAC meeting and outline of
the 1 st day P LambachW Orenstein
1215 - 1225
10" Background
Secretariat view
Technical background/Information needs
from WHO SAGE to estimate impact ofCOVID-19 on immunization programs (for
SAGE working group)
R Hutubessy (WHO) /
Y Sim COVID-19 Session 1: Risk of SARS-CoV-2 transmission with different immunization services1225 - 1240
15" Problem statement
Understanding risk-benefit of proceeding
with immunization services during COVID outbreaks evoke the need for a better understanding of transmission dynamicsQuestions to IVIRAC
oDoes the model address the key analytic question, i.e.,What is the risk of SARS-
CoV-2 transmission to
communities and to health workers: For recommendation Susan Wang 21for settings with various levels of COVID-19 burden, under different health service delivery conditions (e.g., routine immunization via fixed site, outreach, and schools; mass vaccination campaigns which are either fixed-site or door- to-door), and in consideration of the nature and extent of Infection Prevention
Control (IPC) measures
implemented?What is the risk of SARS-CoV-2
transmission to health workers? How robust are the conclusions of the modelling work? Are assumptions about roles of children in transmission justified and sufficiently conservative?How can we extrapolate the results
from the six analysed settings to the other countries? Do country 22characteristics translate into different transmission risks for communities and health workers and if so, how? : Full report on risk of SARS-CoV-2 transmission
1240 - 1300
15'The risk of SARS-CoV-
2 transmission to communities and
to health workers in LMICs under different health service delivery conditionsPresentation of modelling approach to
understand risk of SARS-Cov-2 transmission by varying (I) service delivery (fixed site and house to house campaigns as well as routine outreach), (ii) effectiveness of IPC from 0-95%, (iii) country characteristics (age
pyramid, income levels, urban/rural)K Frey / B Hagedorn
1300-1330
30"Q&A and Discussion of
recommendations to SAGEDiscussion on conclusions for SAGE (to be
continued in closed session)V Pitzer and Joseph Wu
1400 - 1410
10" Impact modelling of potential
COVID vaccines
Update on SAGE WG deliberations on policy-
relevant use case scenarios and modelling needs.Question to IVIRAC:
Are additional epidemiologic and
economic model criteria needed?What is IVIR-AC's advice on
strategies to address knowledge gaps?How could IVIRAC support future
review processes and quality of modelling?Modelling questions
For recommendation A Wilder-Smith
23Fitness-for-Purpose Assessment Report
1410 - 1430
20Modelling approaches and assumptions to
determine the optimal use of a COVID-19 vaccine dependent on vaccine performance and target populationsN Grassly
1430-1500
30" Q&A and Discussion of
recommendations to SAGEDiscussion on conclusions for SAGE (to be
continued in closed session)W Ndifon and J Leask
1500-1510
10quotesdbs_dbs32.pdfusesText_38[PDF] Bilan réglementaire des émissions de gaz à effet de serre (GES) et synthèse des actions de réduction
[PDF] Talent up! Algérie Comment intégrer une Grande Ecole? Zoom sur les écoles de commerce Pour les étudiants issus de formations supérieures de 1 er
[PDF] Bilan d émissions de GES Centre Départemental de Repos et de Soins (CDRS)
[PDF] Cadre de référence de l AAPC et des associations constituantes
[PDF] FISCALITE DES AVOIRS DETENUS A L ETRANGER
[PDF] L établissement d une convention de stage
[PDF] Le Plan Bâtiment Grenelle : Point d étape et actualités
[PDF] MANUEL DU SITE WEB POUR LES AMBASSADEURS
[PDF] les parrains les partenaires
[PDF] ADMISSION SUR TITRES REGLEMENT du CONCOURS AST 2-2013
[PDF] Comité des Œuvres Sociales des Personnels de la Préfecture et du Département des Yvelines C.O.S.P.P.D.Y. CONVENTION D OBJECTIFS ET DE MOYENS
[PDF] MINISTÈRE DES AFFAIRES SOCIALES ET DE LA SANTÉ SANTÉ ÉTABLISSEMENTS DE SANTÉ
[PDF] Site web du Permis Informatique
[PDF] CRÉATION d une MICRO CRÈCHE